HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRLD
Prelude Therapeutics Incorporated
There isn't enough reported data to score PRLD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRLD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
PRLD's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRLD PE Valuation
PRLD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRLD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PRLD's losses to grow, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRLD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.73 | +$0.90 |
| Q1 2026 | -$1.00 | +$0.68 |
| Q4 2025 | -$1.29 | +$0.39 |
| Q3 2025 | -$1.46 | +$0.30 |
| Q2 2025 | -$1.63 | +$0.15 |
| Q1 2025 | -$1.68 | +$0.18 |
| Q4 2024 | -$1.68 | +$0.34 |
| Q3 2024 | -$1.76 | +$0.41 |
PRLD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PRLD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PRLD on profitability, with a higher operating margin.
PRLD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.6M | +41% |
| Q3 2025 | $6.5M | +117% |
PRLD's revenue has grown year over year every quarter since late 2024: $6M last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -271% | N/A |
| Q1 2026 | -310% | N/A |
| Q4 2025 | -308% | +538 points |
| Q3 2025 | -314% | +832 points |
| Q4 2024 | -846% | N/A |
| Q3 2024 | -1146% | N/A |
PRLD's operating margin was −271% last quarter, up 575 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PRLD on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRLD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$15.6M | +$10.5M |
| Q1 2026 | -$21.7M | +$12.6M |
| Q4 2025 | $23.1M | +$43.9M |
| Q3 2025 | -$19.1M | +$8.2M |
| Q2 2025 | -$26.1M | -$2.7M |
| Q1 2025 | -$34.3M | -$2.2M |
| Q4 2024 | -$20.8M | +$3.9M |
| Q3 2024 | -$27.4M | -$1.1M |
PRLD has burned cash in almost every quarter: −$33M over the past year, against −$109M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PRLD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PRLD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +15.9M shares |
| 1 year | +29% | +22.4M shares |
| 3 years | +106% | +50.7M shares |
| 5 years | +118% | +53.3M shares |
PRLD has 98M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRLD Net Leverage
PRLD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRLD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.7 | Neutral |
| Stochastic | 13.3 | Oversold |
PRLD's weekly RSI is 45 (neutral) and its Stochastic is 13 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PRLD PE vs Healthcare Sector
PRLD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRLD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.67 | 4.1% below |
| 20 week MA | $4.46 | 21% below |
| 50 week MA | $3.73 | 5.6% below |
| 100 week MA | $2.39 | 47% above |
| 200 week MA | $3.26 | 8% above |
PRLD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PRLD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.2 | $88.9 | +239% |
| 2021 | $88.9 | $13.7 | -85% |
| 2022 | $13.7 | $5.10 | -63% |
| 2023 | $5.10 | $4.27 | -16% |
| 2024 | $4.27 | $1.34 | -69% |
| 2025 | $1.34 | $2.45 | +83% |
| 2026 YTD | $2.45 | $3.52 | +44% |
PRLD has the edge over HIMS on returns for 2026, with the stronger performance.